about
Oxidative damage to nucleic acids and benzo(a)pyrene-7,8-diol-9,10-epoxide-DNA adducts and chromosomal aberration in children with psoriasis repeatedly exposed to crude coal tar ointment and UV radiation.Genotoxic and apoptotic effects of Goeckerman therapy for psoriasis.Selected Inflammatory and Metabolic Markers in Psoriatic Patients Treated with Goeckerman Therapy.Metabolic Syndrome and Selective Inflammatory Markers in Psoriatic Patients.Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs.Genetic polymorphisms in biotransformation enzymes for benzo[a]pyrene and related levels of benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in Goeckerman therapy.Urinary mutagenicity and genotoxic risk in children with psoriasis after therapeutic exposure to polycyclic aromatic hydrocarbons and ultraviolet radiation.Expression of soluble sCD163 in serum of psoriatic patients is modulated by Goeckerman therapy.Genotoxic hazard and cellular stress in pediatric patients treated for psoriasis with the Goeckerman regimen.Influence of dermal exposure to ultraviolet radiation and coal tar (polycyclic aromatic hydrocarbons) on the skin aging process.Goeckerman Therapy of Psoriasis: Genotoxicity, Dietary Micronutrients, Homocysteine, and Gene PolymorphismsAngiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapyImmunologic changes in TNF-alpha, sE-selectin, sP-selectin, sICAM-1, and IL-8 in pediatric patients treated for psoriasis with the Goeckerman regimenGenotoxic effect of Goeckerman regimen of psoriasisSerum levels of the pro-inflammatory cytokine interleukin-12 and the anti-inflammatory cytokine interleukin-10 in patients with psoriasis treated by the Goeckerman regimenPlasma levels of p53 protein and chromosomal aberrations in patients with psoriasis treated with the Goeckerman regimenMembrane and soluble Toll-like receptor 2 in patients with psoriasis treated by Goeckerman therapyAlarmins HMGB1, IL-33, S100A7, and S100A12 in Psoriasis VulgarisThe Impact of Psoriasis and Metabolic Syndrome on the Systemic Inflammation and Oxidative Damage to Nucleic Acids
P50
Q34097118-2448C9DB-94D1-405F-B028-C4C47014262EQ34115168-31209D68-8BF7-4138-B238-CD241B444F80Q35763690-0885995E-FF4B-410E-8DA2-D205AB4949B4Q37554151-1BC83EA3-E2C5-4A56-979B-91BF0319574FQ37733218-7D93F4E7-48A8-426A-80F3-559DC940FEE4Q39759488-9882DDF9-A6BA-4553-8712-F473C01C5130Q43185724-E276A305-71FC-4C36-956D-DD0B56CB05DCQ45334823-2F447F01-9AEB-481F-ACD5-9982CD5C5731Q51793793-8D388C7B-F98C-47B7-BF53-961C49BDF757Q53218245-46D69325-ECBE-4D1B-8FE2-2615ADC5404DQ64249650-66489549-9126-431D-B82F-189B63244ED0Q79553745-832934E7-2247-4ABB-9AED-97BD00185EF7Q79953258-D39AEA93-0302-43C5-B196-8E3F928FA1DCQ80094758-5AA6BD1F-0799-434D-9F8F-68F2105DCB95Q81810439-716393FC-31CB-4D81-AA34-5D31C94156CDQ82426122-CEB2FF66-8C21-4B36-9A3E-B82AA0FF750DQ85650188-B0AF0534-66D4-4592-A5C3-85F0C21B5E29Q94593316-6681F02B-26AA-4891-BBAC-397CE5D74DB1Q96346767-CEB5501B-5F21-4E36-B0D5-264F449F5BF4
P50
description
researcher ORCID ID = 0000-0002-8580-1485
@en
wetenschapper
@nl
name
L Borska
@ast
L Borska
@en
L Borska
@es
L Borska
@nl
type
label
L Borska
@ast
L Borska
@en
L Borska
@es
L Borska
@nl
prefLabel
L Borska
@ast
L Borska
@en
L Borska
@es
L Borska
@nl
P1153
6602280061
P31
P496
0000-0002-8580-1485